Intra-Cellular Therapies

What Intra-Cellular Therapies does

Intra-Cellular Therapies is a US biopharmaceutical company founded in 2002 by Dr. Sharon Mates, developing small-molecule therapeutics for neuropsychiatric and neurologic diseases of the central nervous system. The company's drug discovery platform is rooted in Nobel Prize-winning research by Dr. Paul Greengard on intracellular signaling, and it operates a PDE1 inhibitor research platform alongside its lead clinical program. Its commercial and clinical assets are concentrated in CAPLYTA (lumateperone), an FDA-approved antipsychotic available in 42 mg, 21 mg, and 10.5 mg capsules, with sequential approvals for schizophrenia (2019), bipolar I/II depression (December 2022), and adjunctive treatment of major depressive disorder (November 2025), plus an April 2026 sNDA for schizophrenia relapse prevention.

The company monetizes CAPLYTA exclusively through US prescription sales distributed via standard pharmaceutical supply chains to outpatient prescribers, supplemented by a Patient Assistance Program for eligible patients at or below 300% of the federal poverty level. It runs direct-to-consumer television advertising, a branded website (caplyta.com), and a healthcare provider medical information service. In April 2025, Johnson & Johnson acquired the company for approximately $14.6 billion, taking it private and folding it into J&J's Innovative Medicine neuroscience segment; CAPLYTA generated $270 million in Q1 2026 quarterly revenue under J&J, representing 8.4% quarter-on-quarter growth.

The clinical differentiation rests on lumateperone's intracellular mechanism of action versus traditional cell-surface receptor approaches, with Phase 3 data showing 63% lower relapse risk in schizophrenia and 84% of patients remaining relapse-free over six months. The pipeline includes ongoing lumateperone indication expansion and a separate PDE1 inhibitor program. The company's historical capital base includes multiple public equity offerings totaling over $500 million in April 2024 alone, and a cumulative funding history spanning from a 2006 non-dilutive grant through repeated post-IPO follow-on offerings prior to the J&J take-private.

Name

Intra-Cellular Therapies

Legal name

Intra-Cellular Therapies, Inc.

Website

http://www.intracellulartherapies.com

Company type

Private

Founded year

2002

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Intra-Cellular Therapies is a US biopharmaceutical company that developed and commercialized CAPLYTA (lumateperone), an FDA-approved treatment for schizophrenia, bipolar depression, and major depressive disorder, based on Nobel Prize-winning intracellular signaling research; the company was acquired by Johnson & Johnson for $14.6 billion in April 2025.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Intra-Cellular Therapies generated revenue through the sale of its FDA-approved drug CAPLYTA (lumateperone) for the treatment of schizophrenia, bipolar depression, and major depressive disorder. The company commercialized the product through traditional pharmaceutical distribution channels.
2. CAPLYTA Revenue: Following acquisition by Johnson & Johnson in 2025, CAPLYTA continued generating revenue, with quarterly sales of $270 million reported in Q1 2026, representing 8.4% quarter-on-quarter growth.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Intra-Cellular Therapies developed and commercialized CAPLYTA (lumateperone), an FDA-approved prescription medication for adults with schizophrenia, depressive episodes associated with bipolar I or bipolar II disorder, and major depressive disorder as adjunctive therapy. The company also advanced a PDE1 inhibitor drug discovery platform and additional lumateperone pipeline indications, all grounded in a proprietary intracellular mechanism-of-action research platform originating from Nobel Prize-winning science.

Product overview

Intra-Cellular Therapies is a biopharmaceutical company focused on developing innovative treatments for psychiatric and neurologic diseases, now part of Johnson & Johnson following its $14.6 billion acquisition in 2025. The company's core product is CAPLYTA (lumateperone), an FDA-approved medication for schizophrenia, bipolar depression, and major depressive disorder. The portfolio includes a Drug Discovery Platform based on Nobel Prize-winning intracellular research, a PDE1 Inhibitor Platform for CNS disorders, and the lumateperone pipeline program exploring additional indications. The company also provides a Patient Assistance Program to support eligible patients.

Differentiator

Problem solved

Functional benefit

Brands

• CAPLYTA: FDA-approved prescription medicine for adults: adjunctive therapy for major depressive disorder (MDD), depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression), and schizophrenia. Available in 42mg, 21mg, and 10.5mg capsules.

Products and services

• CAPLYTA (lumateperone) CAPLYTA is an FDA-approved prescription medication (available in 42 mg, 21 mg, and 10.5 mg capsules) for adults with schizophrenia, depressive episodes associated with bipolar I or bipolar II disorder, and as adjunctive therapy for major depressive disorder. It is sold by prescription only, distributed through standard pharmaceutical supply chains in the US.

Quantifiable outcome

• 63% lower risk of relapse in schizophrenia patients compared with placebo; 84% of patients remained relapse-free over six months
• +2 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Karuna Therapeutics: Developed xanomeline-trospium (Cobenfy), an FDA-approved schizophrenia therapy and one of the most direct competitors to CAPLYTA in the CNS space. Acquired by Bristol Myers Squibb in 2024, making it a comparable CNS-specialty biopharma trajectory.
• Cerevel Therapeutics: CNS-focused biopharma developing emraclidine and other therapies for schizophrenia and Parkinson's disease. Acquired by AbbVie in 2024 — a comparable specialty CNS biopharma with overlapping schizophrenia programs and an analogous 'big-pharma exit' trajectory.
• Sage Therapeutics: CNS-focused biopharma with Zurzuvae (zuranolone) FDA-approved as the first oral therapy specifically for postpartum depression and a development program targeting MDD — directly overlapping with CAPLYTA's MDD indication and representing a peer in specialty CNS commercialization.
• Axsome Therapeutics: CNS-focused biopharma commercializing Auvelity (dextromethorphan-bupropion) for major depressive disorder — a directly overlapping MDD asset — and developing additional CNS therapies. Closely comparable in indication focus, commercial stage, and CNS specialty positioning.
• Acadia Pharmaceuticals: CNS specialty biopharma commercializing NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome. Comparable as a focused CNS commercial-stage biopharma with multi-indication strategy.
• Alkermes: CNS-focused biopharma commercializing Lybalvi (olanzapine/samidorphan) for schizophrenia and bipolar disorder, and Aristada for schizophrenia — directly overlapping with CAPLYTA's approved indications and representing a peer specialty CNS franchise.

Broad incumbents

• Otsuka Pharmaceutical: Established CNS incumbent with Abilify (aripiprazole) and Rexulti (brexpiprazole) across schizophrenia, bipolar, and MDD-adjacent indications. Broad incumbent with overlapping CNS mechanisms serving similar patient populations.
• Sumitomo Pharma America (Sunovion): CNS-focused subsidiary of Sumitomo Pharma that developed and commercializes Latuda (lurasidone) for schizophrenia and bipolar depression — directly comparable approved indications and a meaningful incumbent in the same CAPLYTA-adjacent prescriber base.
• H. Lundbeck: Global CNS-focused biopharma with established franchises in depression, schizophrenia, and neurology. Co-markets Rexulti with Otsuka — a broad CNS incumbent whose portfolio competes for similar prescriber relationships and patient populations as CAPLYTA.
• Johnson & Johnson (Innovative Medicine): Acquirer of Intra-Cellular Therapies and owner of Spravato (esketamine) for treatment-resistant depression and other CNS assets within its Innovative Medicine segment. Relevant as both the parent entity and as a broad incumbent competitor in depression and schizophrenia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/1130875630307409
• LinkedInlinkedin.com/company/intra-cellular-therapies

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intra-Cellular Therapies